SUBSCRIBE
SUBSCRIBE
News   Drug Development

FDA to Meet on Long-Lasting Zyprexa

January 9, 2008 | 
1 min read
WASHINGTON -The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
Clinical research Postmarket research Regulatory
Eli Lilly and Company Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Contemporary art collage. Human hand holding megaphones and spreading fake news. Concept of information, creativity, social issues, rumors. Copy space for ad
Regulatory
After Court Win, Vanda Asks Makary To Review ‘Unacceptable’ Approval of Rival Generics
August 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Regulatory
Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway
August 22, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
 · 
1 min read
 · 
Lori Ellis
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Regulatory
Stealth’s Flight Path Returns to FDA for Rejected Barth Drug
August 21, 2025
 · 
1 min read
 · 
Annalee Armstrong